Biogen, Biovitrum advancing hemophilia drug

Posted In: Life Sciences

By The Associated Press

Monday, October 19, 2009


newsvine diigo google
slashdot
Share
Loading...

Biogen Idec Inc. and Biovitrum said Monday they will move a potential hemophilia B treatment into a late-stage study.

The global study is being designed to assess the safety and effectiveness of the drug candidate rFIXFc in preventing and treating bleeding associated with hemophilia B.

Shares of Biogen rose 31 cents to $49.51 in afternoon trading.

0 Comments

blog comments powered by Disqus

New To Market

more

JEOL to launch world's smallest solid-state NMR probe
JEOL to launch world's smallest solid-state NMR probe

According to JEOL Resonance, a new benchmark for resolution and benchmark will be set with its introduction next week of a new 0.75-mm solid state nuclear magnetic resonance (NMR) probe. The probe is capable of high resolution sample analysis by spinning the sample at 110 kHz, the world's fastest spinning speed for NMR.

Energy Harvesting Subsystems for Wireless Sensors

Nextreme Thermal Solutions has developed two new energy harvesting subsystems for the plumbing and HVAC industries. The subsystems are the latest additions to Nextreme's Thermobility energy harvesting platform that uses thin-film thermoelectric technology to convert available thermal energy into electric power for a variety of autonomous self-powered applications.

Tools & Technology

more

Microscope System with LED Illumination
Microscope System with LED Illumination

Leica Microsystems has introduced the Leica DM4000 B LED, a microscope system with LED illumination suited for biomedical applications.

Liquid Handler

Gilson Inc. has introduced the GX-241 liquid handler, a compact liquid handler suited for application and laboratories where bench space is at a premium.

Advertisement

Advertisement

Top Stories and Headlines
EVERY DAY!

FREE Email Newsletter